Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adicet Bio Inc ACET

Healthcare Biotechnology
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the... see more

Recent & Breaking News (NDAQ:ACET)

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Business Wire 2 days ago

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Business Wire April 8, 2024

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 28, 2024

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Business Wire March 19, 2024

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Business Wire March 11, 2024

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 29, 2024

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Business Wire February 5, 2024

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 31, 2024

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Business Wire January 25, 2024

Adicet Bio, Inc. Announces Pricing of Public Offering

Business Wire January 22, 2024

Adicet Bio, Inc. Announces Proposed Public Offering

Business Wire January 22, 2024

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

Business Wire January 4, 2024

Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

Business Wire January 3, 2024

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 29, 2023

Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting

Business Wire December 10, 2023

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Adicet Bio, Inc. (NASDAQ: ACET)

PR Newswire December 4, 2023

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Business Wire November 8, 2023

Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference

Business Wire November 7, 2023

Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting

Business Wire November 2, 2023

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 31, 2023